Current approaches to adoptive T-cell therapy are limited by the difficulty of obtaining
sufficient numbers of T cells against targeted antigens with useful in vivo characteristics …

In the current adoptive T cell therapy, T cells from a patient are given back to that patient
after ex vivo activation, expansion, or genetic manipulation. However, such strategy …

Adoptive cell transfer (ACT) of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) is a
promising treatment for a variety of malignancies 1. CTLs can recognize malignant cells by …

In currently ongoing adoptive T-cell therapies, T cells collected from the patient are given
back to the patient after ex vivo cell activation and expansion. In some cases, T cells are …

Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer
therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty …

Adoptive T-cell immunotherapy has garnered wide attention, but its effective use is limited by
the need of multiple ex vivo manipulations and infusions that are complex and expensive. In …

Induced pluripotent stem (iPS) cells derived from T lymphocyte (T-iPS cells) preserve the T
cell receptor (TCR) α and β gene rearrangements identical to the original T cell clone. Re …

Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have
facilitated further development of T-cell immunotherapy against wide variety of diseases …

Progress in adoptive T-cell therapy for cancer and infectious diseases, is hampered by the
lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could …

Recent outstanding clinical results produced by engineered T cells, including chimeric
antigen receptors, have already facilitated further research that broadens their applicability …